🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPost-prandial glucose control — GLP-1 vs DPP-4 vs SGLT2i comparison Page 4

Post-prandial glucose control — GLP-1 vs DPP-4 vs SGLT2i comparison

SarahChen_PharmD Thu, May 28, 2026 at 8:19 PM 21 replies 573 viewsPage 4 of 5
nick_newbie
New Member
18
56
Jun 2026
Virginia
Online
Jun 1, 2026 at 7:15 AM#16
newstart_MO said:
There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.

Can confirm. Same sequence, different timescale. I had assumed I was the exception until I read this.

Last edited: Jun 1, 2026 at 10:15 AM
26 1robert_kc, dan_philly, MeganSA_TX and 23 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Jun 1, 2026 at 3:29 PM#17

Clinical perspective, offered as context rather than as advice. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

25 0PharmHunterJen, TomTeleRx, DoseLogDan and 22 others
Reply Quote Save Share Report
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
Jun 1, 2026 at 11:44 PM#18
TrialNerd_Beth said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

24 24jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 21 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Jun 2, 2026 at 7:59 AM#19
TrialNerd_Beth said:
If two explanations both fit, the useful question is which one predicts something the other does not.

There is a second half to this that has not been said yet. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.

Last edited: Jun 2, 2026 at 1:59 PM
23 23SarahChen_PharmD, sarah.morrison, NeuroNate and 20 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 2, 2026 at 4:14 PM#20

Moderator note: a couple of off-topic posts removed. Thread quality here is what the rules are for. Keep it up.

1 1PeptideSynthNJ
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register